Yield of prostate cancer screening at a community based clinic in Saudi Arabia
Objectives: To estimate the incidence and prevalence of prostate cancer in Saudi Arabia.
Methods: This is a retrospective cohort study including male patients aged 40 years and over. The prostate-specific antigen screening tests were carried out in a community-based clinic affiliated with King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia between September 2002 and December 2016.
Results: A total of 2,160 male patients were included in the study. Of these, 1,521 (70%) were Saudi nationals and 639 (30%) were non-Saudi nationals. A total of 108 (5%) patients underwent a prostate biopsy. The biopsy results confirmed that 31 (2%) Saudi patients and 6 (0.93%) non-Saudi patients had prostate adenocarcinoma. The age-standardized incidence rate of prostate cancer in the Saudi male population is 70 per 100,000 males. Nearly two-thirds (71%) of the Saudi patients’ prostate cancer was found to be in the early stages.
Conclusion: The prevalence of prostate cancer in the Saudi male population is higher than that reported by the Saudi Cancer Registry; however, it is low compared with prevalences in developed countries. The mortality rate is also very low. Prostate-specific antigen screening in Saudi Arabia should not be carried out routinely; instead, it should only be carried out on an individual basis.
Saudi Med J 2019; Vol. 40 (7): 681-686
How to cite this article:
Almutairi AA, Edali AM, Khan SA, Aldihan WA, Alkhenizan AH. Yield of prostate cancer screening at a community based clinic in Saudi Arabia. Saudi Med J 2019; 40(7): 681-686. doi: 10.15537/smj.2019.7.24256.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
Chen R, Ren S, Chinese Prostate Cancer Consortium, Yiu MK, Fai NC, Cheng WS, et al. Prostate cancer in Asia: a collaborative report. Asian J Urol 2014; 1: 15-29.
Al-Zahrani AS, Al-Mutlaq HM, Radwi AN, Bazarbashi SM. Cancer incidence reports Saudi Arabia 2014. Riyadh: Saudi Health Council; 2017. p. 83
Alghamidi IG, Hussain II, Alghamdi MS, El-Sheemy MA. The incidence rate of prostate cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry 2001-2008. Hematol Oncol Stem Cell Ther 2014; 7: 18-26.
Rabah DM, Arafa MA. Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis 2010; 13: 191-194.
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419-426
Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
Bell N, Gorber SC, Shane A, Joffres M, Singh H, Dickinson J, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014; 186: 1225-1234.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629.
Segi M, Kurihara M, Tsukahara Y. Cancer Mortality for Selected Sites in 24 Countries: No. 4 (1962-63). Tohoku University, School of Medicine. Department of Public Health; 1966.
Saudi Census. General Authority for Statistics. [Updated 2019. Accessed 2018 February 16th]. Available from: https://www.stats.gov.sa/ar/13
World Cancer Research Fund. American Institute for Cancer Research. Age standardized incidence rate of prostate cancer. [Updated 2007. Accessed 2017 September 9th]. Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/prostate-cancer-statistics
Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O’Brien S, et al. Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med 2013; 173: 866-873.
Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 2002; 3: 19.
Zahir ST, Nazemian MR, Zand S, Zare S. Survival of patients with prostate cancer in Yazd, Iran. Asian Pac J Cancer Prev 2014; 15: 883-886.
Carter, H. Ballentine, Jonathan I. Epstein, Alan W. Partin. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: 126-130.
Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H, et al. The risk factors of prostate cancer: a multicetric case-control study in Iran. Asian Pac J Cancer Prev 2007; 8: 422-428.
O’Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol 2006; 13 Suppl 2: 11-17.
Yu XQ, Luo Q, Smith DP, Clements MS, O’Connell DL. Prostate cancer prevalence in New South Wales Australia: A population-based study. Cancer Epidemiol 2015; 39: 29-36.
Romero FR, Romero AW, Almeida RM, Tambara Filho R. The prevalence of prostate cancer in Brazil is higher in Black men than in White men: systematic review and meta-analysis. Int Braz J Urol 2012; 38: 440-447.
Safarinejad MR. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol 2006; 17: 1166-1171.
Çeber E, Şimşir A, Umar DÇ, Karababa AO, Günaydın G, Çal Ç, et al. Prevalence of prostate cancer among men aged 40+ living in Osman Gazi health care district. Asian Pac J Cancer Prev 2010; 11: 473-478.
- There are currently no refbacks.
Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention. Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.